Challenges Met by PGT

Despite the remarkable progress in next generation sequencing, significant challenges remain.

  • Accuracy: the ability to distinguish between real sequence variants and variants that are artifacts of amplification and sequencing processes
  • Complexity: the ability to link sequence data to the individuals and genes/loci within individuals which are often being assessed as complex heterogeneous populations
  • Phasing (physical linkage): the ability to determine the physical linkage of sequence information frequently produced as short read fragments that need to be stitched together using bioinformatics
  • Cost and speed: the ability to extract key information from a sample without the need to process large numbers of samples through very high throughput next generation sequencing
  • Barriers to competition: PGT has a significant estate of issued patents.

Features of PGT’S Approach




  • Early priority dates: PGT’s innovation is based upon ideas from Nobel Laureate Sydney Brenner a visionary pioneer of molecular biology
  • An understanding of current and future limitations of next generation sequencing: this led PGT to develop approaches to achieving high confidence rare variant detection
  • Broadly applicable technologies: to augment next generation sequencing and meet the needs of a broad range of end applications using the wide range of NGS platforms people commonly use
  • Broad interlocking patent claims: in many instances covering multiple facets of a fundamental approach and/or application with broad issued claims
  • Licensing strategy: designed to enable a range of end users to bring the fruits of PGT’s inventions to market, rather than a focus on keeping our innovations in house
  • Continued innovation: to solve limitations of current and near future technologies in anticipation of the needs of multiple players in the rapidly evolving sequencing sector


There are a wide range of potential clients, collaborators and licensees of PGT’s intellectual properties including, but not limited to, the following:

  • Next Generation Sequence (NGS) Platform Providers: who develop the machines that enable massively parallel sequencing of clonally amplified or single DNA molecules
  • Reagent and device providers to augment NGS platforms: who develop reagents and machines used to add or improve features of broadly adopted sequencing platforms
  • NGS service providers: who use combinations of sequencing platforms and auxiliary devices and reagents to generates masses of sequencing data for any application
  • Molecular diagnostic companies: whose core objectives include the determination of disease predisposition, presence of disease and selection of treatment options
  • Early stage companies: providing reagents, devices and/or services and are looking for ways to strengthen their competitive advantage.